Among Americans aged 60 to 74, only those with certain health conditions need to receive the shots, the agency concluded.
Pfizer’s Abrysvo is one of three R.S.V. vaccines approved by the F.D.A. The other two are GSK’s Arexvy and Moderna’s mRESVIA. Credit…Pfizer, via Associated Press
June 26, 2024 Updated 6:00 p.m. ET (Thanks to Ed M)
In an unusual move, federal health officials revised their recommendations for who should receive the vaccine against the respiratory syncytial virus.
The Centers for Disease Control and Prevention recommended last year that adults age 60 or older could receive a single lifetime dose of an R.S.V. vaccine, in consultation with their health care providers.
On Wednesday, scientific advisers to the agency reframed that guideline. Based on recent safety and effectiveness data, they unanimously recommended that all Americans age 75 and older receive one dose of an R.S.V. vaccine.
But for adults 60 to 74 years of age, the panel endorsed vaccination only for those with certain serious conditions, such as chronic heart or lung disease, advanced kidney disease and diabetes with organ damage.